FDA approves breakthrough drug for metastatic pancreatic cancer: ‘A real revolution’

After decades of efforts to block the tumor-driving RAS protein, the FDA approved daraxonrasib after unprecedented survival gains in metastatic pancreatic cancer; treatment costs about NIS 90,000 a month, raising access concerns | Read More in ynet – Culture